Sartorius Stedim Biotech (CHIX:DIMP) Cyclically Adjusted FCF per Share: €3.22 (As of Mar. 2026)


CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
84 GF Score
Price €179.55
GF Value €207.75
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Cyclically Adjusted FCF per Share?

Sartorius Stedim Biotech CHIX:DIMP 84 Cyclically Adjusted FCF per Share is €3.22 as of Mar. 2026. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €207.75 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Sartorius Stedim Biotech's adjusted free cash flow per share for the three months ended in Mar. 2026 was €1.278. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €3.22 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Sartorius Stedim Biotech's average Cyclically Adjusted FCF Growth Rate was 5.60% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Sartorius Stedim Biotech was 7.50% per year. The lowest was 7.50% per year. And the median was 7.50% per year.

As of today (2026-07-09), Sartorius Stedim Biotech's current stock price is €179.55. Sartorius Stedim Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €3.22. Sartorius Stedim Biotech's Cyclically Adjusted Price-to-FCF of today is 55.76.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Sartorius Stedim Biotech was 161.90. The lowest was 48.87. And the median was 71.72.


Sartorius Stedim Biotech  (CHIX:DIMp) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Sartorius Stedim Biotech's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=179.55/3.22
=55.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Sartorius Stedim Biotech was 161.90. The lowest was 48.87. And the median was 71.72.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Sartorius Stedim Biotech Cyclically Adjusted FCF per Share Related Terms


Sartorius Stedim Biotech Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Cyclically Adjusted FCF per Share Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.50 2.66 2.98 3.04

Sartorius Stedim Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.09 3.01 2.96 3.04 3.22

CHIX:DIMP vs ISRG, BDX, MDLN: Cyclically Adjusted FCF per Share Comparison

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius Stedim Biotech Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Cyclically Adjusted Price-to-FCF falls into.


CHIX:DIMP
84GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sartorius Stedim Biotech's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.278/131.2583*131.2583
=1.278

Current CPI (Mar. 2026) = 131.2583.

Sartorius Stedim Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.000 100.417 0.000
201512 0.000 99.717 0.000
201606 0.000 100.717 0.000
201612 0.000 101.217 0.000
201706 0.000 102.117 0.000
201709 0.000 102.717 0.000
201712 0.000 102.617 0.000
201803 0.117 102.917 0.149
201806 0.039 104.017 0.049
201809 0.213 104.718 0.267
201812 0.183 104.217 0.230
201903 0.526 104.217 0.662
201906 0.300 105.718 0.372
201909 0.531 106.018 0.657
201912 0.526 105.818 0.652
202003 0.968 105.718 1.202
202006 0.603 106.618 0.742
202009 1.138 105.818 1.412
202012 0.083 105.518 0.103
202103 1.535 107.518 1.874
202106 1.222 108.486 1.479
202109 1.038 109.435 1.245
202112 0.296 110.384 0.352
202203 1.025 113.968 1.181
202206 -0.268 115.760 -0.304
202209 0.423 118.818 0.467
202212 0.792 119.345 0.871
202303 0.542 122.402 0.581
202306 0.003 123.140 0.003
202309 -0.114 124.195 -0.120
202312 2.539 123.773 2.693
202403 -0.553 125.038 -0.581
202406 1.430 125.882 1.491
202409 1.918 126.198 1.995
202412 2.108 127.041 2.178
202503 0.560 127.779 0.575
202506 0.494 128.412 0.505
202509 0.680 129.255 0.691
202512 1.337 129.361 1.357
202603 1.278 131.258 1.278

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €3.22 mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a Cyclically Adjusted FCF per Share of €3.22 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's Cyclically Adjusted FCF per Share too high?
Sartorius Stedim Biotech's current Cyclically Adjusted FCF per Share is €3.22. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Cyclically Adjusted FCF per Share compare to ISRG and BDX?
Sartorius Stedim Biotech's Cyclically Adjusted FCF per Share of €3.22 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Cyclically Adjusted FCF per Share is €3.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €207.75, compared to a current price of €179.55 — trading 13.6% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €3.22. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Cyclically Adjusted FCF per Share is €3.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €179.55 is trading 13.6% below its estimated GF Value™ of €207.75. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for CHIX:DIMP:

  • Cyclically Adjusted FCF per Share: €3.22
  • GF Value™: €207.75 vs. price of €179.55 (13.6% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score

Get the complete analysis for CHIX:DIMP

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€179.55
Price
€207.75
GF Value